1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,750 | 7,050 | 06.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Eisai, Henlius Strike Japan Commercialization Deal for PD-1 Antibody Serplulimab | 3 | Contract Pharma | ||
| Fr | Eisai, Henlius partner on anti-PD-1 antibody in Japan | 2 | Investing.com | ||
| Fr | Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan | 289 | JCN Newswire | TOKYO and SHANGHAI, Feb 6, 2026 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu... ► Artikel lesen | |
| Do | Eisai signs $388m deal for Japanese rights to Henlius' anti-PD-1 mAb | 3 | Pharmaceutical Technology | ||
| SHANGHAI HENLIUS BIOTECH Aktie jetzt für 0€ handeln | |||||
| Do | Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan | 321 | PR Newswire | TOKYO and SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Eisai Co., Ltd. ("Eisai") and Shanghai Henlius Biotech, Inc. ("Henlius") today announced the conclusion of an exclusive commercialization... ► Artikel lesen | |
| Do | HENLIUS (02696): INSIDE INFORMATION ANNOUNCEMENT - LICENSE AGREEMENT WITH EISAI IN RESPECT OF HANSIZHUANG | 1 | HKEx | ||
| Mi | HENLIUS (02696): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
| Mi | HENLIUS (02696): INSIDE INFORMATION ANNOUNCEMENT - COMPLETION OF THE H SHARE FULL CIRCULATION | - | HKEx | ||
| 27.01. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF HLX43 FOR INJECTION (AN ANTI-PD-L1 ANTIBODY-DRUG CONJUGATE) IN COMBINATION ... | - | HKEx | ||
| 20.01. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG APPLICATION FOR A PHASE 1B/2 CLINICAL TRIAL OF HLX701 (RECOMBINANT HUMAN SIRPA - IGG4 ... | - | HKEx | ||
| 19.01. | HENLIUS (02696): INSIDE INFORMATION ANNOUNCEMENT - LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE FOR THE H SHARE FULL CIRCULATION OF THE COMPANY | 1 | HKEx | ||
| 16.01. | Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026 | 210 | PR Newswire | SAN FRANCISCO, Jan. 16, 2026 /PRNewswire/ -- The 44th J.P.Morgan Healthcare Conference (JPMHC) was successfully held in San Francisco, the United States, from January 12 to 15. On January... ► Artikel lesen | |
| 16.01. | HENLIUS (02696): INSIDE INFORMATION ANNOUNCEMENT - ISSUANCE OF THE FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION BY THE COMPANY | 2 | HKEx | ||
| 13.01. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - BIOLOGICS LICENSE APPLICATION (BLA) FOR HANBEITAI (BEVACIZUMAB INJECTION) HAS BEEN ACCEPTED BY THE UNITED STATES ... | 1 | HKEx | ||
| 31.12.25 | HENLIUS (02696): POLL RESULTS OF THE RESOLUTION PROPOSED AT THE 2025 FOURTH EXTRAORDINARY GENERAL MEETING HELD ON WEDNESDAY, 31 DECEMBER 2025 | 3 | HKEx | ||
| 31.12.25 | HENLIUS (02696): CONTINUING CONNECTED TRANSACTIONS | 1 | HKEx | ||
| 29.12.25 | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF HLX37 (RECOMBINANT HUMANISED ANTI-PD-L1 AND ... | 4 | HKEx | ||
| 23.12.25 | Henlius CEO Dr. Jason Zhu to Deliver a Keynote Presentation at JPM 2026 | 744 | PR Newswire | SHANGHAI, Dec. 23, 2025 /PRNewswire/ -- The 44th J.P. Morgan Healthcare Conference will take place from January 12 to 15, 2026, in San Francisco, USA. Dr. Jason Zhu, Executive Director and... ► Artikel lesen | |
| 19.12.25 | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION FOR THE PHASE 1 CLINICAL TRIAL OF NIVOLUMAB BIOSIMILAR HLX18 (RECOMBINANT ... | 4 | HKEx | ||
| 12.12.25 | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) FOR HANSIZHUANG (SERPLULIMAB INJECTION) IN COMBINATION WITH CHEMOTHERAPY FOR NEO-/ ... | 1 | HKEx |
1 2 3 4 Weiter >>
74 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | Diagnostikkonzern Qiagen überrascht im Schlussquartal - Weiteres Wachstum 2026 | VENLO/HILDEN (dpa-AFX) - Qiagen hat 2025 von einer anziehenden Nachfrage nach seinen Kernprodukten profitiert. Dabei lief das Schlussquartal besser als vom Labordienstleister und Diagnostikkonzern... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 64,62 | +4,24 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,990 | +8,23 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ERASCA | 12,290 | +3,45 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| AGOMAB THERAPEUTICS | 14,650 | 0,00 % | AgomAb Therapeutics N.V.: Agomab Announces Pricing of Initial Public Offering | ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 62,19 | +0,10 % | Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns | ||
| RECURSION PHARMACEUTICALS | 3,960 | +11,24 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 74,96 | +2,39 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| IMMUNOVANT | 27,040 | +12,39 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 | IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 29,770 | +5,53 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| SPYGLASS PHARMA | 26,400 | 0,00 % | SpyGlass Pharma Prices IPO At $16 Per Share | WASHINGTON (dpa-AFX) - SpyGlass Pharma, Inc. (SGP), a late-stage biopharmaceutical company, announced the pricing of its initial public offering of 9.38 million shares at $16 per share.The company... ► Artikel lesen | |
| LIMINATUS PHARMA | 1,840 | -10,24 % | Liminatus Pharma, Inc. - 8-K, Current Report | ||
| DAY ONE BIOPHARMACEUTICALS | 11,410 | +8,87 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen |
Das Unternehmen SHANGHAI HENLIUS BIOTECH INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,300 (+4,62 %) liegt der Kurs bei 6,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI HENLIUS BIOTECH INC finden Sie auf Wallstreet Online.